Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | Combo: Protein & vector vaccines |
| Study Type: | Phase IIb |
| Species: | Human |
| Stage: | Follow-up (closed to accrual) |
| Study Start Date: | 2017-10-31 |
| Study Made Public: | NA |
Title
A multicenter, randomized, double-blind, placebo-controlled Phase 2b efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 in preventing HIV-1 infection in women in sub-Saharan Africa
Description
HVTN 705/HPX2008 (Imbokodo) is a Phase IIb clinical trial evaluate the safety and immunogenicity of Ad26.Mos4.HIV (Ad26) and Clade C gp140.
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.